The cytolytic T lymphocyte (CTL) response has often been used to assess the reconstitution of T cell function after allogeneic or autologous bone marrow transplantation (BMT). Less is known, however, about the reconstitution of the CTL response after peripheral blood stem cell transplantation (PBSCT). Therefore, we investigated the CTL response against Epstein-Barr virus (EBV) of patients undergoing autologous PBSCT. CTLs of six patients with relapsed non-Hodgkin's lymphoma and multiple myeloma were established before and at different times after PBSCT by in vitro stimulation of peripheral blood lymphocytes with autologous EBVtransformed lymphoblastoid cell lines (LCLs). The efficiency of T cell priming by LCLs was assessed at the time of initiation of CTL lines; the proliferative response was strongly reduced during the first 4 months and increased 5 months or more following PBSCT. Cytolytic activity was measured after three or four restimulations of CTLs. All patients investigated had a detectable EBV-specific CTL response which was poor during the first weeks after transplantation, accompanied by a strong non-MHC-restricted cytotoxic activity and a high proportion of CD56-positive T cells. Five or more months after PBSCT, a specific CTL response against EBV was seen which was similar to the situation prior to PBSCT, while the unspecific cytotoxic response decreased. Blocking experiments with monoclonal anti-CD3, anti-CD8 or anti-MHC I antibodies resulted in substantial inhibition of autologous LCL lysis, whereas anti-CD4 or anti-MHC II antibodies had no effect. Finally, autologous PHA blasts of a patient with the HLA haplotype A1/9+, B5/8+, Cw4/7+, were loaded with various EBNA-derived nonapeptides known to be presented by HLA B8 or A11, and exposed to autologous, EBV-directed 
In the last few years, autologous peripheral blood stem cell transplantation (PBSCT) has been established as a standard treatment for relapsed aggressive non-Hodgkin's lymphoma and has proven advantageous when compared with autologous or allogeneic bone marrow transplantation (BMT). [1] [2] [3] [4] [5] However, in contrast to autologous or allogeneic BMT, little information is available concerning the reconstitution of the immune system following autologous peripheral blood stem cell transplantation (PBSCT). As after BMT, the CD4/CD8 ratio seems to be inversed after PBSCT, but lymphocyte subpopulations and functions recover more rapidly, including the proliferative response to mitogens and the cytotoxic activity of lymphocytes after stimulation with high-dose IL-2 (lymphocyte-activated killer cells, LAK). [6] [7] [8] [9] [10] Previous investigations mainly examined non-specific lymphocyte functions in patients undergoing autologous PBSCT and the reconstitution of the antigen-specific cytolytic T lymphocyte (CTL) response has not been evaluated so far. Therefore, we examined the CTL response of these patients to Epstein-Barr virus (EBV), a widespread lymphotropic herpes virus. Most people are infected with EBV by adulthood, and the life-long persistence in epithelial cells and B lymphocytes, as an asymptomatic latent infection, is controlled by one of the strongest human CTL responses. 11, 12 This surveillance is based mainly on CD8-positive HLA-restricted memory T cells found in the peripheral blood of seropositive individuals which can be reactivated in vitro by challenge with autologous EBVinfected B cells. [13] [14] [15] [16] [17] In immunosuppressed individuals, reactivation of this latent EBV infection can lead to the outgrowth of EBV-transformed B lymphocytes with unregulated polyclonal or monoclonal lymphoproliferation, of which the latter has a rapidly progressive and uniformly fatal course. 18, 19 For this reason, the EBV-directed CTL response has been carefully investigated after allogeneic BMT, where up to 30% of the recipients of allografts from mismatched or matched unrelated donors may develop EBV lymphoma. 20 , 21 The aims of our study were: (1) to determine whether a specific EBV-directed cytolytic activity exists after PBSCT; (2) to characterize this CTL response; and (3) to analyze qualitatively this CTL response in some patients with lymphoid malignancies early vs late after PBSCT. By these means we wished to determine whether the assessment of the EBV-specific CTL response can be used as a surrogate marker for the reconstitution of the antigen-specific T cell response after PBSCT.
Patients and methods

Patients
The patients investigated in this study included six adults with a mean age of 55.6 years (range 48-60 years) with hematological malignancies who underwent high-dose chemotherapy and autologous PBSCT at the Medizinische Klinik Innenstadt, University of Munich. Three patients received transplants for follicular (or centroblasticcentrocytic) lymphoma (WH, MP, HR), one for mantle cell (or centrocytic) lymphoma (KS), one for immunoblastic lymphoma (EF) and one for plasmocytoma (NM). Before transplantation, the patients were treated with different cytoreductive regimens (see Table 1 ). For all patients, procedural risks were explained and informed consent was obtained. Peripheral blood stem cells were collected after IEV polychemotherapy (ifosfamide, epirubicine, VP-16) followed by administration of G-CSF (Neupogen; Amgen, Munich, Germany); pretransplant conditioning regimens were high-dose busulfan (16 mg/kg) and cyclophosphamide ␣IFN = interferon alpha; Alexanian = prednisone and melphalan; BU/CY = busulphan and cyclophosphamide; CDVP-16 = cyclophosphamide/dexamethasone/VP-16; COP = cyclophosphamide, vincristine, prednisone; COAEPP = cyclophosphamide, vincristine, adriamycin, procarbazine, prednisone, VP-16 (etoposide); COPBLAM = cyclophosphamide, vincristine, prednisone, bleomycin, procarbazine; CYD/TBI/ABMT = cyclophosphamide/dexamethasone/total body irradiation/autologous bone marrow transplant; IEV = ifosphamide, epirubicine, VP-16 (etoposide); IMVP-16 = ifosphamide, methotrexate, VP-16; Knospe = chlorambucil and prednisone; VAD = vincristine, adriamycin, prednisone; VMCP = vincristine, melphalan, cyclophosphamide, prednisone; ib = immunoblastic; cb-cc = centroblastic-centrocytic; cc = centrocytic; F = female; M = male; NHL = nonHodgkin's lymphoma.
(120 mg/kg) for NHLs or high-dose melphalan for plasmocytoma. Details of the methods of PBSC collection and of the transplantation protocol have been described elsewhere. [22] [23] [24] The titers of IgG antibodies specific for the viral capsid antigen (VCA) of EBV were determined for all patients before and after transplantation and were in the seropositive range (Ͼ1:10) in each case. HLA-typing of patient WH was carried out by the Laboratory for Immunogenetics at the Poliklinik, University of Munich (Dr Scholz, Professor Albert).
Establishment and culture of EBV-transformed lymphoblastoid cell lines (LCLs)
Twenty milliliters of heparinized blood were collected from each patient and peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque density gradient centrifugation. 10 7 PBMCs were incubated with EBV-containing supernatant of the marmoset cell line B95-8 for 2 h; thereafter, three parts of RPMI 1640 (GIBCO, Gaithersburg, MD, USA) containing l-glutamine (2 mm), gentamycin (100 g/ml), 10% FCS and 1 g/ml cyclosporin A (Sandoz, Basel, Switzerland) were added. After 3 weeks of incubation in a humidified 37°C, 5% CO 2 incubator, outgrowing LCLs were maintained by splitting 1:3 in complete RPMI 1640 media once a week. Characterization by flow cytometry using FITC-and PE-conjugated mAb (DianovaImmunotech, Hamburg, Germany) revealed a homogeneous CD3-negative, CD19-, CD20-, CD23-positive cell population.
Generation of EBV-specific CTLs
EBV-specific CTL reactivity in patients was evaluated at different times after PBSCT and, where available, compared to the response before transplantation. PBMC were obtained from heparinized blood by Ficoll-Hypaque density gradient centrifugation and depleted from monocytes by adherence to plastic dishes over 45 min. Non-adherent lymphocytes were distributed into 24-well tissue culture plates (Nunc, Wiesbaden, Germany) at a concentration of 1 × 10 6 /ml and coincubated with 2.5 × 10 4 irradiated (8000 rad) autologous LCLs in RPMI 1640 supplemented with l-glutamine (2 mm), penicillin (100 g/ml), streptomycin (100 g/ml) and 15% human AB serum (Serva, Heidelberg, Germany). After 1 week and subsequently at weekly intervals, T cells were harvested, washed, recultured at 5 × 10 5 /well in fresh T cell medium (RPMI containing the same additives as above plus 20 U/ml human recombinant interleukin-2 (hrIL-2, Boehringer Mannheim, Mannheim, Germany) and 30% culture supernatant of the MLA 144 cell line 25 as additional source of IL-2) and restimulated with irradiated autologous LCLs at a responder to stimulator ratio of 10:1. Rapidly expanding CTL lines were split and fed according to their growth rates.
Proliferation assay
At the time of initiation of CTL cultures the proliferative response to autologous LCLs and concanavalin-A (Con-A) was determined. Freshly isolated monocyte-depleted PBMCs were distributed at 10 5 /100 l into 96-well flatbottom culture plates (Nunc) and stimulated with 10 4 /100 l irradiated autologous LCLs in RPMI 1640 containing 10% FCS and suboptimal concentrations of Con-A (0.5 g/ml; Sigma, Munich, Germany); maximal proliferation in response to 0.5 mg/ml phytohemagglutinin (PHA; Difco, Detroit, MI, USA) served as a control. After 4 days, cells were pulsed with 0.5 Ci/well 3 H-thymidine (Amersham, Braunschweig, Germany) per well for 16 h, harvested onto filters, dried and counted in a Wallac Microbeta Plus 1450 scintillation counter (Turku, Finland). Proliferation induced by Con-A alone was defined as background proliferation of 1.0; LCL-induced additional proliferation was related to Con-A stimulation, and the response to both stimuli was expressed as stimulation indices.
Cytotoxicity assay
Anti-EBV cytotoxic activity was tested after three or four restimulations of CTLs in standard 51 Cr release assays. Target cells included autologous LCLs, the NK-sensitive K562 cell line (a gift of Dr Christian Strasburger, Medizinische Klinik, Munich, Germany), and autologous PHA blasts for the peptide binding assays. After labeling with 100 Ci 51 Cr (Dupont, Bad Homburg, Germany) for 90 min, target cells were distributed at 5000/50 l into 96-well V-bottom plates in RPMI 1640 supplemented with l-glutamine, gentamycin (concentrations as above) and 10% FCS. Effector T cells were added in triplicate in varying E:T ratios (2.5:1 to 20:1) in a volume of 100 l. In blocking experiments, labeled target cells were preincubated for 30 min with the MHC class I antibody W6-32 or the MHC class II-specific antibody L243 in a concentration of 1:10; alternatively, CTLs were preincubated with 10 g/ml anti-CD3, anti-CD4 or anti-CD8 (all antibodies were kindly provided by Professor Rieber, Institut für Immunologie, Munich, Germany). After incubation for 4 h in a humidified 5% CO 2 atmosphere, 50 l of supernatant were harvested and counted in a microplate scintillation counter (Packard, Dreieich, Germany). Percent specific lysis was calculated as (experimental release − spontaneous release) × 100/(maximum release − spontaneous release), where spontaneous release was determined by incubating target cells in medium alone, and maximum release by adding 10% Triton X-100. Spontaneous release was between 3 and 5% of maximum release. For each cytotoxicity assay, a phenotypic analysis of the effector T cell population was performed by double-staining flow cytometry using FITC-and PE-conjugated MAb to CD3, CD4, CD8 and CD56 (Dianova-Immunotech).
Peptide binding assay
For characterization of the anti-EBV CTL response of patient WH, autologous PHA blasts were generated by stimulation of PBMCs with 100 g/ml PHA for 3 days and subsequent expansion in IL-2 containing T cell media. PHA blasts were labeled with 51 Cr as described and preincubated for 30 min with 4 × 10 −7 mol/l of one of two different EBNA-derived nonapeptides: QAKWRLQTL (EBNA 3A-derived) and IVTDFSVIK (EBNA 3B-derived) which were shown to be HLA-B8-and HLA-A11-restricted, respectively. 16, 17 Peptide sequences were kindly provided by D Moss, Queensland Institute of Medical Research, Brisbane, Australia; 17 peptide synthesis was carried out by Dr Georg Arnold, Genzentrum, München, Effector T cells were added and the assay was continued as described above.
Results
Proliferation of peripheral blood mononuclear cells in response to autologous, EBV-immortalized B cells (LCLs) and to concanavalin-A (Con-A)
At the time of initiation of autologous CTL lines, proliferation of freshly isolated peripheral blood mononuclear cells (PBMCs) was measured to assess the efficiency of T cell priming, using Con-A and autologous LCLs as stimulators. Maximal PHA stimulation served as a control (not shown). EBV-induced proliferation of PBMCs could be detected in all patients (Figure 1 ), but was weaker during the first 4 months (patients EF, NM, KS and HR; median stimulation index of 2.54, range 2-3.19) than more than 4 months following PBSCT (patients KS, WH and MP, median stimulation index of 6.12, range 5.47-51.97). All patients were seropositive for EBV at the time of examination. Proliferation relative to conA stimulation 
Cytolytic activity against EBV before and at different times after PBSCT
The EBV-specific CTL response was examined at different times following PBSCT and, where available, compared to the CTL response before transplantation. The data of all examined patients are listed in Table 2 , where % lysis of autologous LCLs demonstrates the EBV-specific CTL response, and % lysis of the NK-sensitive K562 cell line illustrates the non-specific cytolytic response.
Representative findings of several patients are demonstrated in Figure 2 . Figure 2a , b and c show the cytolytic response of patient KS. Before PBSCT, a strong LCLdirected lysis between 22% (E:T ratio 2.5:1) and 31% (E:T ratio 20:1) and only a weak non-specific lysis of the NKsensitive K562 cells (3.6-20%) was seen (Figure 2a) . Three months after PBSCT, the cytolytic response of the same patient was dominated by a strong nonspecific response against K562 (20-45%); whereas the specific lysis of LCLs was very weak (4.8-11%) (Figure 2b ). At 5 months post-PBSCT, the strength of the anti-EBV response seemed similar to pre-transplantation levels (15-29% specific lysis), and the nonspecific K562-directed lysis was decreased (2.4-29%) (Figure 2c) . Comparable results were obtained in patient NM who started with a weak LCLdirected CTL response (11.6-22.6% lysis) and already a quite strong K562-directed lysis (5-40%) before transplantation (Figure 2d ). One month after PBSCT, this nonspecific cytotoxic response was further increased (15-52% K562 cell lysis), and the specific EBV-directed cytotoxicity was clearly lower than before PBSCT (4-13% specific lysis) (Figure 2e ). Further follow-up investigations of this patient were not possible. Finally, Figure 2f shows another patient (WH) whose anti-EBV response was investigated 11 months after PBSCT; the specific anti-EBV-CTL response dominated over a negligible nonspecific response (19.6-29% specific lysis; 0.1-3% lysis of K562 cells).
The remaining patients gave comparable results (see Table 2 ). The specific CTL response of EF was weak before PBSCT (5.6-10% specific lysis); it further decreased during the first 2 months following PBSCT, but became stronger after 3 months (7.2-17.8% specific lysis). As in patients KS and NM, the nonspecific cytolytic response increased significantly early after transplantation (30-54% lysis of K562 cells) compared to pre-PBSCT values (6.6-24% lysis of K562 cells). Patient HR, who was investigated 4 months after PBSCT, showed a comparatively strong specific and nonspecific CTL response; whereas in patient MP a strong specific CTL response (5.6-20.4% specific lysis) dominated over a negligible nonspecific cytolytic activity (1.57-8.3%) at 9 months following PBSCT. Table 3 demonstrates the immunophenotype of the anti-EBV CTL lines as analyzed by flow cytometry. The strong, nonspecific cytotoxic response shortly after PBSCT was paralleled by a relatively high proportion of CD56-positive T cells at that time (21.8% in patient KS, 38% in patient EF, 50.9% in patient NM) in comparison with the CTL lines established pre-PBSCT or at later times after PBSCT, where CD8-and CD4-positive cells were predominant.
Blocking of the EBV-specific CTL response by monoclonal antibodies
For characterization of the cell surface molecules involved in specific T cell recognition of autologous LCLs, MAb blocking studies were carried out. Figure 3 shows a representative example of one patient (WH). A substantial inhibition of autologous LCL lysis was observed after pretreatment of effector T cells with saturating concentrations of anti-CD3 and -CD8 (10.9% and 12% of specific LCL lysis, respectively, compared to 20% of specific lysis by untreated CTLs), but not with anti-CD4 MAbs (18.8% of specific lysis); accordingly, individual LCL targets were protected from lysis by pretreatment with MAbs to framework determinants on HLA class I antigens but not by anti-MHC class II MAbs (3.83 vs 20.9% of specific LCL lysis).
The cytolytic T cell response against EBV after autologous PBSCT is MHC class I-restricted
In order to evaluate the specificity and MHC restriction of the CTL response against EBV following PBSCT, we performed a set of experiments, where the cytolytic response of CTLs of one patient (WH) generated by repeated stimulation with autologous LCLs was tested using autologous PHA blasts as targets (Figure 4) . Autologous PHA blasts were preincubated either with medium alone or with one of two different EBNA-derived nonapeptides: QAKWRLQTL (EBNA 3A-derived) presented by HLA-B8, thereby fitting the patient's HLA haplotype (HLA-A1/9, -B5/8, Cw4/7), or IVTDFSVIK (EBNA 3B-derived) which is HLA-A11-restricted. 17 A substantial lysis was seen only after loading 913 Table 2 EBV-directed cytotoxic activity of patients undergoing autologous PBSCT The EBV-directed specific CTL response is represented by the % specific lysis of autologous LCLs of each patient at different E:T ratios; whereas the % lysis of the NK cell-sensitive K562 cell line illustrates the unspecific cytolytic response. Where available, the CTL response before PBSCT was evaluated (KS, NM, EF); other patients are only shown at one time point following PBSCT.
of PHA blasts with the HLA-B8-restricted QAKWRLQTL peptide, while preincubation with the IVTDFSVIK peptide restricted to HLA-A11 which was not part of the patients haplotype, induced only very little cell lysis. Untreated PHA blasts were not lysed at all ( Figure 4 ).
Discussion
High-dose chemotherapy followed by transplantation of autologous peripheral blood progenitor cells has become standard treatment for young patients with relapsed nonHodgkin's lymphoma. 1 While the transplantation of PBSCs has clearly been proven to accelerate hematopoietic recovery compared to BMT, [2] [3] [4] little is known about the reconstitution of the immune system following PBSCT. In particular, no data were available concerning the T cell response to specific antigens in PBSCT patients. In order to address this question, we analyzed the specific CTL activity directed against EBV in patients with relapsed non-Hodgkin's lymphoma undergoing autologous PBSCT.
It has been speculated that specific cytolytic T cells directed against EBV are absent from the peripheral blood for a 3-6 month period following HLA-matched, allogeneic bone marrow transplantation. 26 Although our study included only a few patients, our data indicate that this might not be the case after autologous PBSCT. All patients investigated had a detectable EBV-specific CTL response, which was weak during the first weeks after autologous PBSCT. The appearance of a strong nonspecific cytotoxic activity during this time was an inversion of the situation before transplantation, where the majority of these patients had a strong EBV-specific CTL response. At later times (Ͼ4 months) following PBSCT, specific anti-EBV activity was reconstituted, whereas the relative contribution of the non-MHC-restricted cytotoxic response decreased.
The increased nonspecific cytolytic activity after PBSCT (including NK and especially LAK cells) has been reported previously. It has been shown that this part of the cellular immune response regenerated faster and more potently than after autologous or allogeneic BMT; this is in accordance with faster recovering total lymphocyte counts and the fact that CD56-positive cells are among the earliest regenerating cells following transplantation as documented by immunophenotypic analyses of peripheral blood lymphocytes in these patients. 6, 10, 27, 28 Our findings showing a significantly increased percentage of CD56-positive cells in the effector T cell population in patients investigated early after PBSCT are in agreement with these studies.
In the literature, there were no data with regard to the CTL response against specific antigens such as EBV following PBSCT. In contrast, the anti-EBV CTL response has been carefully investigated in patients undergoing allogeneic BMT. Lucas et al 29 found profound deficiencies in the EBVdirected CTL precursor frequencies up to 3 months following allogeneic BMT, and a recovery over the following 3-6 months in most patients. Given the limited number of patients studied, our results can only show a trend with regard to the time course of reconstitution of the anti-EBV CTL response in autologous PBSCT. However, the data seem to fit the above findings in allogeneic BMT. It should be emphasized that a reliable assessment of the time required for a complete reconstitution of the anti-EBV CTL response will need the investigation of larger numbers of patients. and f) shows the CTL response of patient NM before (d), after 1 month (e) and of patient WH (f) 11 months after PBSCT. The EBV-specific CTL response is indicated in closed circles, whereas unspecific lysis of K562 cells is shown in open symbols. Percent specific lysis was calculated as (experimental release − spontaneous release) × 100/(maximum release − spontaneous release); spontaneous release was between 3 and 5% of maximum release.
An impaired T helper cell function during the first weeks following PBSCT might contribute to the weak CTL activity at this time. The poor EBV-induced proliferative response of PBMC at this time in those patients who developed only a minor EBV-specific cytolytic activity would support this argument (Figure 1) . A defective function of T helper cells has also been demonstrated in BMT recipients by others. [30] [31] [32] [33] Concerning the nature of antiviral cytotoxic responses following BMT, Tilkin et al 34 could demonstrate MHC restriction of the specific cytolytic response against Herpes simplex virus-1 (HSV-1) and EBV for 12 patients within 2 months after allogeneic BMT. Their findings were in contrast to Crawford et al 26 and Duncombe et al, 35 who found that the anti-EBV response after BMT even in long-term follow-up patients (up to 17 months post transplant) was primarily MHC unrestricted. The failure to find a MHCrestricted CTL response was probably due to the fact that unprimed PBMC were tested for cytotoxicity without antigen-specific restimulation. Our results of the EBV-directed CTL response following PBSCT suggest that the weak specific activity seen early after transplantation regenerates to a strong, MHC class I-restricted CTL response. Although blocking experiments were not undertaken in all patients investigated, the data obtained showed the same characteristics for the EBV-specific CTL response as reported for healthy individuals. [13] [14] [15] It can be substantially blocked by antibodies directed against CD3 or CD8, while anti-CD4 or anti-MHC class II show no effect, and the main effector cells are CD8-positive CTLs. MHC class I restriction is further underlined by experiments using EBNA-derived nonapeptides presented by autologous PHA blasts, which demonstrated that the EBV-directed CTLs recognize only the peptide known to be associated with HLA-B8 (therefore matching the patients HLA-haplotype), whereas another, HLA-A11-restricted EBV-peptide did not lead to a significant lysis.
16,17 Thereby we could verify that the anti-EBV 
Figure 4
Recognition of an EBNA-derived MHC-restricted peptide epitope by anti-EBV CTLs of patient WH 11 months after PBSCT. EBVspecific CTLs were established against autologous LCLs. Cytotoxic activity was measured at an E:T ratio of 20:1 using autologous PHA blasts as targets, which were preincubated with medium alone or one of two different EBNA-derived nonapeptides: QAKWRLQTL (EBNA 3A-derived) which is known to be presented by HLA-B8 and IVTDFSVIK (EBNA 3B-derived) which is known to be presented by HLA-A11. The patient's haplotype was HLA-A1/9, B5/8, Cw4/7.
response following PBSCT is directed against peptides which are recognized in the context of the patient's individual HLA class I molecules. These are constitutive features of a specific CTL response. Taken together, our findings suggest that the analysis of the EBV-directed CTL activity is a very useful method for the evaluation of post-transplant recovery of antigenspecific T cell function in patients undergoing autologous PBSCT. Further studies are needed with larger series of patients undergoing different pre-treatment regimens to determine the time of CTL reconstitution after PBSCT.
